Cancer immunotherapies
by design™
iTeos Therapeutics is pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for patients.
At iTeos, we specialize in targeted immunotherapies for people living with cancer.
We leverage our deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies.
Our two clinical stage programs, EOS-448 and Inupadenant, were designed with the aim of having best-in-class properties. We are moving rapidly into late stage clinical trials to explore the full potential of our science.
As a responsible company, we are committed to building Environmental, Social and Governance (ESG) principles into how we operate to create sustainable value for society and all of our stakeholders.
Our pipeline
Our efforts are targeting various cancer indications using our drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations.
The following information provides an overview of our dynamic pipeline of cancer therapy development. Studies underway are grouped by our primary drug therapies, and listed out by combination with other treatments. Indications for each combination under study, along with the current and planned phases of each study, are included.
iTeos drug trials move through five phases:
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
iTeos drug trials move through five phases:
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Following is a list of drug combinations currently under study with:
EOS-448
as well as the indication for each.
drug combo and indication:
+ dostarlimab | 1L NSCLC PDL1high
status of study phases:
Phase 3, planned
drug combo and indication:
+ dostarlimab | 1L NSCLC PDL1high
status of study phases:
Phase 2, active
drug combo and indication:
+ dostarlimab | 1L HNSCC PDL1high / low
status of study phases:
Phase 2, active
drug combo and indication:
+ dostarlimab + chemotherapy | 1L mNSCLC
status of study phases:
Phase 1, active
drug combo and indication:
+ dostarlimab + CD96 | Advanced Malignancies
status of study phases:
Phase 1, active
drug combo and indication:
+ dostarlimab + PVRIG | Advanced Malignancies
status of study phases:
Phase 1, active
drug combo and indication:
Monotherapy/+ iberdomide | Relapsed Refractory Multiple Myeloma
status of study phases:
Phase 2, active
Following is a list of drug combinations currently under study with:
Inupadenant
as well as the indication for each.
drug combo and indication:
Monotherapy | High Biomarker
status of study phases:
Phase 2, active
drug combo and indication:
+ pembrolizumab | PD-1 Resistant Melanoma
status of study phases:
Phase 2, active
drug combo and indication:
+ chemotherapy | Post-IO Chemo-naive NSCLC
status of study phases:
Phase 2, active
Following is a list of drug combinations currently under study with:
EOS-984
as well as the indication for each.
drug combo and indication:
Monotherapy | Advanced Malignancies
status of study phases:
Phase 1, planned
Studies with dark backgrounds are active. Studies with light backgrounds are planned.
There has never been a better time to work at iTeos.
As a leading clinical-stage biotech, our innovative science-driven work is fascinating and potentially lifesaving.
Whether it is working in our laboratory or in our offices, you will help people live healthier lives. You will find yourself on the forefront of science, within a high-tech environment where no two days are the same.
Latest press releases
iTeos Provides Business Updates and Clinical Development Plans for 2023
– 2023 will produce significant advances for both anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant – Eleven…
iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2023 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company…
